Education
About Us
Working with TipRanks
Follow Us
4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
FDMT Stock Chart & Stats
$8.61
-$0.14(-2.20%)
At close: 4:00 PM EST
$8.61
-$0.14(-2.20%)
Day’s Range― - ―
52-Week Range$2.24 - $12.34
Previous CloseN/A
Volume165.32K
Average Volume (3M)736.92K
Market Cap
$439.55M
Enterprise Value$400.35M
Total Cash (Recent Filing)$402.65M
Total Debt (Recent Filing)$21.41M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
May 07, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares Outstanding51,051,487
10 Day Avg. Volume751,996
30 Day Avg. Volume736,921
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)0.86
Price to Sales (P/S)5.10
P/FCF Ratio-3.98
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue4.70
Enterprise Value/Gross Profit-33.47
Enterprise Value/Ebitda-2.51
Forecast
1Y Price Target
$33.17Price Target Upside285.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.48
Revenue Forecast (FY)$19.01M
Bulls Say, Bears Say
Bulls Say
Early Clinical Durability And TolerabilityEarly-phase clinical data showing good tolerability and durable effects across difficult-to-treat patients increase confidence in the platform's ability to deliver sustained therapeutic benefit.
Late-stage Trial EnrollmentCompletion and ahead-of-expectation enrollment in the pivotal Phase 3 wet age-related macular degeneration trial signals strong investigator and patient interest and supports an upcoming pivotal readout that could validate the therapy.
Strategic Partnership And FundingA strategic collaboration with a major pharmaceutical partner supplies upfront funding, cost sharing, milestone payments and tiered royalties, reducing development risk and strengthening commercialization prospects.
Bears Say
Competitive Retina LandscapeA busy retina market with multiple competing anti-VEGF therapies progressing could pressure market share and pricing for the wet AMD candidate, challenging commercial prospects even with positive data.
Cystic Fibrosis Development UncertaintyModest interim results in the cystic fibrosis program combined with small patient numbers and an unclear link between biomarker changes and clinical function raise development risk and may complicate regulatory planning.
Real-world Adoption RiskInitial market uptake could be constrained because clinicians may prefer established intravitreal treatments and newly emerging oral options, limiting early use to patients not controlled by conventional therapies.
4D Molecular Therapeutics News
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $2.23 and its highest was $12.34 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
4D Molecular Therapeutics’s market cap is $439.55M.
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 45 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on Mar 18, 2026. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of -$0.528 by $0.958.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -1.01.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 51,051,487 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of $0.43 in its last earnings report, beating expectations of -$0.528. Following the earnings report the stock price went up 4.907%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Currently, no hedge funds are holding shares in FDMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4D Molecular Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.17 (285.25% Upside)
$33.17 (285.25% Upside)
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Bullish
Bullish news 60%
Bearish news 40%
Bearish news 40%
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.09%
12-Months-Change
Fundamentals
Return on Equity
-47.27%
Trailing 12-Months
Asset Growth
-29.81%
Trailing 12-Months
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
FDMT Stock 12 Month Forecast
Average Price Target
$33.17
▲(285.25% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Design Therapeutics
―
Immuneering
―
Aura Biosciences Inc
―
Ownership Overview
0.38% Insiders
13.65% Mutual Funds
43.86% Other Institutional Investors
25.02% Public Companies and
Individual Investors